Dean M. Messing

发表

Predicting drug-drug interactions in drug discovery: where are we now and where are we going?

M. Hutzler, Dean M. Messing, L. Wienkers, 2005, Current opinion in drug discovery & development.

Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.

Dean M. Messing, G. Anderson, J. Monahan, 2011, Bioorganic & medicinal chemistry letters.

Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.

Dean M. Messing, G. Anderson, J. Monahan, 2011, Bioorganic & medicinal chemistry letters.

Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress.

Dean M. Messing, A. Bahinski, R. Gallavan, 2009, Journal of pharmacological and toxicological methods.

Mechanistic Investigations of Test Article–Induced Pancreatic Toxicity at the Endocrine–Exocrine Interface in the Rat

Steven A. Bailey, D. Morris, Dean M. Messing, 2014, Toxicologic pathology.

Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis

Jason M. Edmonds, Dean M. Messing, E. Peeva, 2013, The Journal of Immunology.

GlomerulonephritisLupus and Antibody-Mediated Selective Inhibition of BTK Prevents Murine

Shashi, Jason M. Edmonds, Nagappan, 2013 .

Modeling the Clinical Phenotype of BTK Inhibition in the Mature Murine Immune System

Jason M. Edmonds, Dean M. Messing, M. Ruzek, 2014, The Journal of Immunology.

System Inhibition in the Mature Murine Immune Modeling the Clinical Phenotype of Btk

Jason M. Edmonds, Dean M. Messing, M. Ruzek, 2022 .

Application of blood microsampling in cynomolgus monkey and demonstration of equivalent monoclonal antibody PK parameters compared to conventional sampling

Dean M. Messing, A. Joyce, B. Gorovits, 2021, Pharmaceutical Research.

Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes.

Dean M. Messing, A. Bendele, O. Nemirovskiy, 2010, Arthritis and rheumatism.

Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.

Dean M. Messing, G. Anderson, J. Monahan, 2011, Bioorganic & medicinal chemistry letters.

Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase.

Dean M. Messing, J. Monahan, J. Portanova, 2010, Bioorganic & medicinal chemistry letters.

A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics

P. Jasper, J. Tolsma, Dean M. Messing, 2020, CPT: pharmacometrics & systems pharmacology.

Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.

David C. Wood, K. Fennell, R. Kurumbail, 2018, Journal of medicinal chemistry.

Studies with neutralizing antibodies suggest CXCL8-mediated neutrophil activation is independent of C-C motif chemokine receptor-like 2 (CCRL2) ligand binding function

Dean M. Messing, M. Hegen, J. Brooks, 2023, PloS one.

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.

Dean M. Messing, J. Collins, Michelle A. Schmidt, 2016, Journal of medicinal chemistry.

Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study

Dean M. Messing, S. Tarabar, K. Page, 2020, Clinical pharmacology in drug development.

Anti-Inflammatory Properties of a Novel N-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation

Dean M. Messing, J. F. Schindler, G. Anderson, 2009, Journal of Pharmacology and Experimental Therapeutics.

Discovery and Characterization of Atropisomer PH‐797804, a p38 MAP Kinase Inhibitor, as a Clinical Drug Candidate

Dean M. Messing, G. Anderson, J. Monahan, 2012, ChemMedChem.

Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase.

R. Kurumbail, Dean M. Messing, J. F. Schindler, 2011, Bioorganic & medicinal chemistry letters.

Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.

Daniel P. Walker, Dean M. Messing, A. Wittwer, 2018, ACS medicinal chemistry letters.

Acute Lymphoid and Gastrointestinal Toxicity Induced by Selective p38α Map Kinase and Map Kinase–Activated Protein Kinase-2 (MK2) Inhibitors in the Dog

David R. Anderson, J. Kramer, J. Sagartz, 2010, Toxicologic pathology.

Modeling the Clinical Phenotype of BTK Inhibition in the Mature Murine Immune System

Jason M. Edmonds, Dean M. Messing, M. Ruzek, 2014, The Journal of Immunology.